

S. 1662, Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act

As ordered reported by the Senate Committee on Health, Education, Labor and Pensions on May 25, 2021

By Fiscal Year, Millions of Dollars	2021	2021-2026	2021-2031
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Increase or Decrease (-) in the Deficit	0	0	0
Spending Subject to Appropriation (Outlays)	0	30	not estimated
Statutory pay-as-you-go procedures apply?	No	Mandate Effects	
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2032?	No	Contains intergovernmental mandate?	No
		Contains private-sector mandate?	No

S. 1662 would authorize the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) to increase funding transfers to the Reagan-Udall Foundation and the Foundation for the National Institutes of Health, respectively, up to an annual cap of \$5 million each. The foundations are 501(c)(3) organizations created by the Congress to support the missions of FDA and NIH. CBO anticipates that the agencies would transfer the maximum authorized amounts to the foundations each year, about \$38 million more than authorized under current law over the 2022-2026 period. CBO estimates that costs associated with the increased transfers would total \$30 million over the 2021-2026 period; any spending would be subject to the availability of appropriated funds.

The CBO staff contact for this estimate is Ryan Greenfield. The estimate was reviewed by Leo Lex, Deputy Director of Budget Analysis.